AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...
The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a historically difficult organ to drug: the kidney. Judo Bio debuted Monday after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback